SERIOUS ADVERSE EVENTS MICROREPORTS

Serious Adverse Events by System Organ Class (S.O.C.)
Pfizer’s data in Pfizer’s own words

Data from Pfizer’s Post Marketing Experience Document 5.3.6

Microreport 1: Blood System – Hematology. hemorrhage/bleeding/blood counts

Microreport 2: Thromboembolic SOC – clots and emboli. 151 cases in the first 3 months.

Microreport 3: Strokes. 275 patients (61 of which were fatal)

Microreport 4: Liver. Five Deaths Within 20 Days of Pfizer’s mRNA COVID Injection. 50% of Adverse Events Occurred Within Three Days

Microreport 5: Cardiovascular. 77% of Cardiovascular Adverse Events from Pfizer’s mRNA COVID Shot Occurred in Women, as well as in people under age 65. Two Minors Suffered Cardiac Events

Microreport 6: Pediatric. Infants and Children Under 12 Given the Pfizer mRNA COVID “Vaccine” Seven Months BEFORE Pediatric Approval. 71% of Adverse Event Cases Classified as Serious

Microreport 7: Neurological. 542 Neurological Adverse Events, 95% Serious, in First 90 Days of Pfizer mRNA Vaccine Rollout. 16 Deaths. Females Suffered AEs More Than Twice As Often As Males.

Microreport 8: Bells Palsy. 449 Patients Suffer Bell’s Palsy Following Pfizer mRNA COVID Vaccination in Initial Three Months of Rollout. A One-Year-Old Endured Bell’s Palsy After Unauthorized Injection

Microreport 9: Renal/Kidney. Acute Kidney Injury and Acute Renal Failure Following Pfizer mRNA COVID Vaccination. 33% of Patients Died

Microreport 10: Anaphylaxis. In the First Three Months of Pfizer’s mRNA “Vaccine” Rollout, Nine Patients Died of Anaphylaxis. 79% of Anaphylaxis Adverse Events Were Rated as “Serious.”

Microreport 11: Immune-Mediated/Autoimmune. Including 12 Fatalities. Pfizer Undercounted This Category of Adverse Events by 270 Occurrences

Microreport 12: Vasculitis. 34 Blood Vessel Inflammation, Vasculitis, Adverse Events Occurred in First 90 Days After Pfizer mRNA “Vaccine” Rollout, Including One Fatality. Half Had Onset Within Three Days of Injection. 81% of Sufferers Were Women

Microreport 13: Musculoskeletal. Afflicted 8.5% of Patients in Pfizer’s Post-Marketing Data Set, Including Four Children and One Infant. Women Affected at a Ratio of Almost 4:1 Over Men

Microreport 14: Other AESIs. Included MERS, Multiple Organ Dysfunction Syndrome (MODS), Herpes Infections, and 96 DEATHS. 15 Patients Were Under Age 12, Including Six Infants

Microreport 15: Dermatological. Women Suffered 94% of Dermatological Adverse Events Reported in First 90 Days of Pfizer COVID “Vaccine” Rollout. 80% of These Adverse Events Were Categorized As “Serious.”

Microreport 16: Respiratory. Thirty-Two Percent of Pfizer’s Post-Marketing Respiratory Adverse Event Patients Died, Yet Pfizer Found No New Safety Signals

Microreport 17: Pregnancy and Lactation. 23% of Vaccinated Mothers’ Fetuses or Neonates Died. Suppressed Lactation and Breast Milk Discoloration Reported.

Microreport 18: Vaccine Failure. 2.5 Months After COVID Vaccine Rollout, Pfizer Changed Criteria for ‘Vaccination Failure,’ Causing 99% of Reported Cases to Not Meet That Definition. 3.9% of Reported ‘Lack of Efficacy’ Cases Ended in Death in First 90 Days of Public Vaccine Availability

Microreport 19: COVID. Pfizer’s ‘Post-Marketing Surveillance’ Shows mRNA-Vaccinated Suffered 1000s of COVID Cases in 1st 90 Days of Vaccine Rollout. Most Infections in the Vaccinated Categorized as ‘Serious Adverse Events.’

Microreport 20: Vaccine Associated Enhanced Disease. 100s of Possible Vaccine-Associated Enhanced Disease (VAED) Cases in First 3 Months of Pfizer’s mRNA COVID Vaccine Rollout, Yet Public Health Spokespeople Minimized Their Severity by Calling Them “Breakthrough Cases.”